Horizon Quantum Computing to Establish First-of-a-Kind…

Monmouth Junction, NJ. (December 4, 2013): TYRX, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) clearance for expanded indications in marketing the AIGISRx® N Antibacterial Envelope for use with spinal cord neuromodulators. This comes after the recent FDA clearance of the AIGISRx N for use with vagus nerve stimulators. This expanded clearance extends TYRX’s leadership in the commercialization of implantable medical devices designed to help reduce Surgical Site Infections (SSIs) associated with implantable devices in the fields of neurosurgery and cardiology.